PROGRAM OUTLINE:

Introduction to Cancer: Focus on Solid Tumors
October 17-18, 2017
Newark Liberty International Airport Marriott - Newark, NJ

Description:

Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.

Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer. Each session will be presented by clinicians active in these areas and will focus on overall patient presentation and management and cancer diagnosis and staging. Following these sessions, our experts will lead delegates in interactive group discussions on the key issues relating to effective management of each tumor type.

Topics to be discussed:
- Cancer: Terminology and classification
- Anti-cancer drugs & side effects including immunotherapies
- New developments in cancer therapy
- Introduction to the major tumor types: breast, lung, melanoma, upper gastrointestinal (GI), colorectal, ovarian and prostate cancer
- Clinical trials

Who Should Attend:

Introduction to Cancer: Focus on Solid Tumors is designed to meet the broad information and education requirements of a range of pharmaceutical and biotech personnel from R&D, medical affairs, regulatory, strategic marketing and many others from both science and business functions.

Course Instructors:

Stéphanie Gaillard, M.D.
Director, Gynecologic Cancers
Assistant Professor of Oncology, Assistant Professor of Gynecology & Obstetrics
Johns Hopkins Kimmel Cancer Center

www.healthtech.com/ioc
Rebecca Suk Heist, M.D.
Assistant Professor in Medicine, MGH Cancer Center,
Massachusetts General Hospital, Harvard Medical School

Bert O’Neil, M.D.
Professor of Medicine
Director, Phase 1 and GI Oncology Program, Simon Cancer Center
Indiana University School of Medicine

Jeffrey Peppercorn, M.D.
Associate Professor Department of Medicine Harvard Medical School and Director, Survivorship Program
Massachusetts General Hospital

Susan Slovin, M.D.
Attending Physician, Member, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, Professor of Medicine,
Weill-Cornell Medical College

Administrative/Venue Details:
The registration fee at CHI’s VIP Discount Rate is $4,495 USD (regular rate $4,995 USD). You save 10% off your registration by registering through our marketing partner, Cambridge Healthtech Institute (CHI). This includes lunch and refreshments throughout the day. Accommodation costs are not included in the course fee. However, Healthcare has organized a special bed and breakfast rate the venue who require overnight accommodation – details of how to book will be provided with the joining instructions for the course.

Delegates can register on-line or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records. Details of the venue will be supplied on registration.

Course Schedule at-a-Glance:

Tuesday, October 17: 8:15 am – 4:30 pm

Registration – Continental breakfast available

8:55 am Welcome/Opening Remarks

Introduction to Cancer
• Clarification of terminology
• Classification of tumor types
• Principles of treatment and review of treatment options
  - chemotherapy / biological / hormonal / targeted
  - radiotherapy
  - surgical intervention
    • Adjuvant and neoadjuvant therapy
    • Endpoint assessment (response/survival)

Introduction to Anti-Cancer Drugs and Side-Effects
• Classification of anti-cancer drugs
• Mechanisms of action
• Mono vs. combination therapy
• Chemotherapy regimes

www.healthtech.com/ioc
• Dose intensity and outcome
• Immunotherapies

Tea/coffee

Clinical Trials – Overview

12:00 pm Lunch

Prostate Cancer
• Epidemiology
• Patient presentation
• Diagnosis and management
• Treatment of localized disease
• Treatment of advanced disease – locally and metastatic

Prostate Cancer Case Presentations and Discussion

Tea/coffee

Breast Cancer
• Epidemiology
• Diagnosis and staging
• Review of surgical procedures
• Chemotherapeutic options
• Role of hormonal therapy

Breast Cancer Case Studies and Discussion

4:30 pm Close

Wednesday, October 18, 2017: 8:15 am – 4:20 pm

8:15 am Continental breakfast available

Upper Gastrointestinal (GI) Cancer (esophagus, stomach, pancreas)
• Epidemiology
• Patterns of presentation
• Diagnosis and management
• Surgery

Upper GI Case Presentations and Discussion

Tea/coffee

Colorectal Cancer
• Epidemiology
• Patterns of presentation
• Diagnosis and management
• Surgery
• Chemotherapy

Colorectal Cancer Case Presentations and Discussion

Lung Cancer
• Epidemiology
• Small cell vs. non-small cell cancer
• Patient presentation
• Treatment options

Lung Cancer Case Presentations and Discussion

12:45 pm Lunch

Ovarian Cancer
• Epidemiology
• Diagnosis and staging
• Review of surgical procedures
• Chemotherapeutic options
• Role of hormonal therapy

Ovarian Cancer Case Presentations and Discussion

Tea/Coffee

Melanoma
• Epidemiology
• Classification
• Diagnosis, staging and prognosis
• Current treatment options, their strengths and limitations

Discussion

Summary /Closing Remarks

4:20 pm END OF COURSE
About our Course Instructors:

Dr. Stéphanie L. Gaillard

Dr. Stéphanie L. Gaillard is a Medical Oncologist who specializes in the treatment of gynecologic malignancies and is the Director of Gynecologic Cancer Trials at the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Gaillard has a particular interest in the use of targeted biologic and immune-based therapies for recurrent ovarian, uterine, and cervical cancers.

Stéphanie Gaillard earned her doctoral degree in cancer biology and medical degree from the Duke University Medical Center (North Carolina) in 2006. She received residency training in Internal Medicine at the Johns Hopkins School of Medicine (Maryland) from 2006-2009 followed by fellowship training in Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine (Maryland), from 2009-2012. She is board certified in Medical Oncology as well as Internal Medicine.

Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to chemotherapy.

Dr. Rebecca Suk Heist

Dr. Rebecca Suk Heist has a clinical practice focused on patients with lung and esophageal cancer. My research focus is on clinical trials of novel agents. As part of the Termeer Center, I lead and participate in first-in-human studies of targeted agents across a broad range of tumor types, with a particular focus in lung. Dr. Heist is a contributing author of many articles - many can be found on PubMed.

Bert H. O’Neil, M.D.

Bert Howard O’Neil, M.D., has been named the inaugural Joseph W. and Jackie J. Cusick Professor of Oncology and a Professor of Medicine at the Indiana University (IU) School of Medicine, in Indianapolis. He is also the Phase I Director and Director of the Gastrointestinal Cancer Research Program at the IU Melvin and Bren Simon Cancer Center, and he represents the cancer center on the Big Ten Cancer Research Consortium steering committee.

As the Phase I Director, Dr. O’Neil oversees phase I clinical trials for all areas of cancer treatment. Dr. O’Neil’s primary area of expertise is in gastrointestinal cancers, with a particular concentration on pancreas, colorectal, and hepatocellular carcinomas. He also has considerable expertise in targeting new drugs to specific molecular targets on tumors.

Dr. O’Neil was most recently an Associate Professor of Medicine and Director of the Gastrointestinal Malignancies Research Program at the University of North Carolina at Chapel Hill. He also was the Medical Director of the UNC Lineberger Comprehensive Cancer Center’s clinical protocol office where he designed and conducted clinical and translational studies.

Dr. O’Neil earned his BS in biology at the University of California at Irvine and his MD at the UCLA School of Medicine. After graduating, he completed his residency in internal medicine at the University of California at San Francisco. His fellowship in hematology and oncology was also conducted at the University of California at San Francisco.

www.healthtech.com/ioc
Jeffrey Peppercorn, M.D., MPH

Dr. Peppercorn is a hematologist/oncologist with special interests in breast cancer, medical ethics, and trial accrual. He trained at Harvard Medical School, completed internal medicine residency at Massachusetts General Hospital, and completed his hematology/oncology fellowship training at the Dana-Farber Cancer Institute. His clinical specialty is breast cancer and he is currently an Associate Professor of Medicine at Duke University. He is recent Chair of the ASCO Ethics Committee and Chair of the CALGB/Alliance Ethics committee and serves as a member of the ASCO Task Force on Cost of Cancer Care. His research ranges from clinical trials of novel therapeutics for breast cancer to studies of accrual to clinical trials and medical ethics and he is the author of numerous publications, reviews, and chapters on these topics.

Select Publications:


Susan F. Slovin, M.D., Ph.D.

Dr. Slovin is Attending Physician in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I. Weill Medical College of Cornell University. She earned her doctorate in pathobiology from Columbia University and her medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. Her postdoctoral training included a fellowship in clinical immunology through Scripps Clinic & Research Foundation, La Jolla, California; an internship and a residency in internal medicine from The Mount Sinai Hospital in New York; and a
hematology/oncology fellowship in the Department of Medicine, Memorial Sloan-Kettering Cancer Center.

She is a board-certified medical oncologist with expertise in the areas of prostate cancer immunology and clinical trial design. A noted immunologist, she has been leading an initiative which focuses on the development of novel immunologic approaches for the treatment of prostate cancer. This includes assuming the leadership of the Prostate Immunotherapy Group sponsored by the Prostate Cancer Foundation whose challenge is to develop guidelines for development of immune therapy clinical trials in prostate cancer. She is a member of several professional associations, including the American Society of Clinical Oncology, American Association of Immunologists, American Association of Investigative Pathology, and American Association of Cancer Researchers, American Urologic Association and Sigma Xi Research Society. An ad hoc reviewer for numerous journals, including Cancer, Cancer Immunology and Immunotherapy, JAMA, Cancer Research, and Clinical Cancer Research, New England Journal of Medicine, Urology and Journal of Urology, she also served as Associate Editor for Seminars in Oncology as well as the editorial boards of several major journals including Clinical Cancer Research. She is also a member of the NCI Clinical Oncology Study Section, ad hoc reviewer for the DOD, AACR, and NCI SPORE panels and serves as Chair of the VA Merit Grant Review System.

Dr. Slovin is well-recognized in the area of prostate cancer immunotherapy and has contributed many peer-reviewed articles and reviews to the medical literature. She has received numerous accolades and was recognized by CancerCare as the 2003 Physician of the Year. She was the keynote speaker in 2008 at the Massachusetts Prostate Cancer Coalition.
Course Registration Form

Introduction to Cancer: Focus on Solid Tumors
October 17-18, 2017
Newark Liberty International Airport Marriott - Newark, NJ

Fill out and fax back to Kris Waterman at +1 781-972-5425.

If you are paying by check or have any questions regarding payment, please call +1 781-972-5400. To inquire about a group discount, call +1 781-972-5472 or email cunningham@healthtech.com

Fee: VIP Discount Rate $4,495 USD (regular rate $4,995 USD). Hotel and travel costs are not included.

YOUR DETAILS:
Title: (tick applicable)   __ Dr.     __ Mr.     __ Mrs.     __ Ms.     __ Miss     __ Other
_________________________________________________________________
First Name                                                                 Last Name
Company  Job Title
Department  Address
City  State  Country
Telephone  Fax  Email

Charge my credit card
___ VISA     ___MasterCard     ___American Express
_________________________________________________________________
Name (as it appears on card)
Accout Number
Start Date (mm/yy)  End Date (mm/yy)
_______________________________________________
Security Number (from rear/front of card)
_________________________________________________________________
Signature

Please note: No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more than 20 working days prior to course date will incur a $175 (USD) administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then please let us know.

www.healthtech.com/ioc